Orphan designation was granted by the FDA to Curis (CRIS) Inc’s emavusertib for the treatment of primary central nervous system lymphoma, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRIS: